The biopharma Roivant Sciences (Nasdaq:ROIV) has decided to cut roughly 100 employees from its 891-person workforce. According to CEO Matt Gline, the company decided on the reorganization to allow sufficient cash runway to last until the second half of 2025. In the quarter that ended September 30, 2022, the company had a net loss of…